Show simple item record

dc.contributor.authorCampbell, J
dc.contributor.authorRyan, CJ
dc.contributor.authorBrough, R
dc.contributor.authorBajrami, I
dc.contributor.authorPemberton, HN
dc.contributor.authorChong, IY
dc.contributor.authorCosta-Cabral, S
dc.contributor.authorFrankum, J
dc.contributor.authorGulati, A
dc.contributor.authorHolme, H
dc.contributor.authorMiller, R
dc.contributor.authorPostel-Vinay, S
dc.contributor.authorRafiq, R
dc.contributor.authorWei, W
dc.contributor.authorWilliamson, CT
dc.contributor.authorQuigley, DA
dc.contributor.authorTym, J
dc.contributor.authorAl-Lazikani, B
dc.contributor.authorFenton, T
dc.contributor.authorNatrajan, R
dc.contributor.authorStrauss, SJ
dc.contributor.authorAshworth, A
dc.contributor.authorLord, CJ
dc.date.accessioned2016-09-14T09:49:43Z
dc.date.issued2016-03-15
dc.identifier.citationCell reports, 2016, 14 (10), pp. 2490 - 2501
dc.identifier.issn2211-1247
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/109
dc.identifier.eissn2211-1247
dc.identifier.doi10.1016/j.celrep.2016.02.023
dc.description.abstractOne approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase genetic dependencies in 117 cancer cell lines from ten cancer types. By integrating the siRNA screen data with molecular profiling data, including exome sequencing data, we show how vulnerabilities/genetic dependencies that are associated with mutations in specific cancer driver genes can be identified. By integrating additional data sets into this analysis, including protein-protein interaction data, we also demonstrate that the genetic dependencies associated with many cancer driver genes form dense connections on functional interaction networks. We demonstrate the utility of this resource by using it to predict the drug sensitivity of genetically or histologically defined subsets of tumor cell lines, including an increased sensitivity of osteosarcoma cell lines to FGFR inhibitors and SMAD4 mutant tumor cells to mitotic inhibitors.
dc.formatPrint-Electronic
dc.format.extent2490 - 2501
dc.languageeng
dc.language.isoeng
dc.publisherCELL PRESS
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectProtein Kinases
dc.subjectReceptor, erbB-2
dc.subjectRNA, Small Interfering
dc.subjectGene Expression Profiling
dc.subjectRNA Interference
dc.subjectMutation
dc.subjectReceptor, Fibroblast Growth Factor, Type 1
dc.subjectSmad4 Protein
dc.titleLarge-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.
dc.typeJournal Article
dcterms.dateAccepted2016-02-01
rioxxterms.versionofrecord10.1016/j.celrep.2016.02.023
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-03-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCell reports
pubs.issue10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Ashworth Collaborators
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Ashworth Collaborators
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function
pubs.publication-statusPublished
pubs.volume14
pubs.embargo.termsNot known
icr.researchteamComputational Biology and Chemogenomics
icr.researchteamAshworth Collaborators
icr.researchteamFunctional Genomics
icr.researchteamGene Function
dc.contributor.icrauthorCampbell, James
dc.contributor.icrauthorChong, Yu-Shing
dc.contributor.icrauthorAl-Lazikani, Bissan
dc.contributor.icrauthorNatrajan, Rachael
dc.contributor.icrauthorLord, Christopher


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0